IDEAYA Biosciences (IDYA) said Monday the US Food and Drug Administration granted breakthrough therapy designation to its experimental neoadjuvant treatment, darovarsetib, to treat adult patients with primary uveal melanoma.
The company said the decision was supported by interim data from an ongoing phase 2 trial, which showed 82% ocular tumor shrinkage and 61% eye preservation rates in patients.
IDEAYA said it plans to initiate a phase 3 trial for the therapy in H1 2025.
The breakthrough therapy designation accelerates developing and reviewing promising therapies for serious conditions, offering benefits such as intensive FDA guidance and priority review.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。